Neutropenia is an unusually low amount of neutrophils, which are a form made up of white blood cell. These cells constitute the majority of lymphocytes in circulation and assist in protecting your body from infection by bacteria virus, viruses, along with other harmful microorganisms.

This report focuses on the Neutropenia Biologic Market for Drug Treatment. It comprises drugs that increase creation of neutrophils. These drugs are sold through hospitals, retail pharmacies, as well as online pharmacies. Key players in the market include Spectrum Pharmaceuticals, Evive Biotech, Cellerant Therapeutics, and BeyondSpring Pharmaceuticals.

Neutropenia Biologic Drug Treatment Market anticipated to grow at a CAGR of 6.4% to reach US$ 18.68 Billion by the end of 2030

Get Sample with Latest Trends and Future Advancements https://marketreportservice.com/request-sample/neutropenia-biologic-drug-treatment-market-54406

Growth Driver

Neutropenia is a disease that is defined by a lower count of neutrophils in blood. They are a form of white blood cells that shields the body from infection caused by viruses, bacteria as well as other pathogens. In the event of a decrease in neutrophils, patients more vulnerable to infections, which could cause fever - also known as chemotherapy-induced febrile neutropenia (CINF).

Neutropenia is among the most severe hematologic toxicity from chemotherapy. To overcome this adverse effect, a variety of medications are on the market to boost the number of blood cells.

An increasing quantity of individuals are getting chemotherapy for a variety of illnesses which include cancer. This is driving the demand for safe and effective treatments to minimize the negative side negative effects that chemotherapy can cause, including neutropenia. This is why the market for treatment for neutropenia is growing at an impressive growth rate.

Furthermore there are a lot of players in the treatment for neutropenia marketplace are investing their money into the development of new products. For example, Amgen launched Neulasta (pegfilgrastim) delivery kit in April 2017. The kit is created to enhance the comfort of patients and aid in getting the therapeutic benefits they desire from the medication.

Furthermore, in Nov-2019, Sandoz, a subsidiary of Novartis, got FDA approval for Ziextenzo (pegfilgrastim-bmez). The drug helps decrease the frequency of infections that manifest as febrile neutropenia, which is common among cancer patients who receive myelosuppressive anti-cancer drugs that cause significant clinical neutropenia.

Segmentation

A global biologic neutropenia treatment market is extremely scattered, and there are several players. Some of the leading players in the market include Amgen Inc., BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd. (Kirin Holdings Company Limited), Pfizer Inc., Sandoz Inc. (Novartis AG), Teva Pharmaceutical Industries Ltd and many more.

These companies have taken strategic strategies like launches of new products, mergers and acquisitions, as well as partnerships to increase their presence in the treatment for neutropenia market.

Key Segments

Key Segment by Type

• Filgrastim
• Pegfilgrastim
• Lenograstim
• Lipegfilgrastim
• Sargramostim

Key Segment by Application

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Chemotherapy-induced neutropenia is caused by the lack of neutrophils found in blood, a form that is a type of white blood cells. The patient is vulnerable to infections and could even cause death if not treated promptly. The increase in cases of cancer, the most common cause of neutropenia caused by chemotherapy, is accelerating the development in this industry.

Additionally the introduction of novel medications and novel drug delivery techniques has helped to boost the expansion in this industry. Additionally, new treatments that decrease the number of injections are anticipated to accelerate the market's growth.

Furthermore, the growing prevalence of febrile neutropenia is helping to boost the growth of the market. The report provides a thorough review of the competitive landscape and offers profiles of the most prominent companies in this market. The profiles cover business plans, products & services and key developments and SWOT analysis of the particular firms.

Recent Development

In January 2023, the US FDA approved a new biologic drug called Rukobia (fostemsavir) for the treatment of neutropenia in patients with HIV infection. Rukobia is a fusion inhibitor that works by blocking the entry of the virus into immune cells, thereby reducing the risk of infection and neutropenia.

The market for treatment of neutropenia is driven by creation of new therapies, coupled with a rise in the incidence of neutropenia caused by chemotherapy. Innovative delivery methods for medication enhance the patient's experience and, in turn, increases compliance and drives the market.

Additionally, since cancer is the primary reason for neutropenia caused by chemotherapy increasing the frequency of cancer treatment could boost the growth of the market.

Recently, Pfizer received the FDA approval for NIVESTYM (filgrastim-aafi) it is the biosimilar drug to Neupogen. The introduction of the drug broadens availability of critical treatments for neutropenia. In addition, the major players in the treatment for neutropenia market are proactively promoting research and development and are also driving the growth of the market.

In February of 2018, Partner Therapeutics signed an agreement with Sanofi to purchase Leukine (sargramostim) by Sanofi, which is a subsidiary of the company. The acquisition provides Partner with access to the only FDA-approved recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) and enables it to accelerate the expansion of its portfolio of CIN drugs.

Besides, emerging pipeline therapies such as Rolontis (eflapegrastim injection), EC-18, ALRN-6924, Romyelocel-L/CLT-008, Plinabulin, and F-627 offer a strong competitive edge and a potential to disrupt the Chemotherapy Induced Febrile Neutropenia market once approved.

These treatments explore new mechanisms of action and are targeted to treat patients who are at moderate-to-high risk of developing CIN. Therefore, they dramatically improve the prognosis for the idiosyncratic condition of drugs-induced neutropenia.

Regional Outlook

The world-wide neutropenia biologic drug market is predicted to expand quickly in the coming years. The reason for this is because of the growing rates of cancer all over the world which, results in the need for treatment for neutropenia.

Additionally, the major players in this field are also working to spread awareness of preventive measures, early detection and the most effective treatment options for neutropenia.

Febrile Neutropenia is among the most frequently encountered side effects of chemotherapy. It significantly reduces the likelihood of curing the disease. It's caused by a variety of factors, such as a lower immune system that can slow the progression of treatment, leads to premature termination of doses and reduces the possibility of providing a successful treatment.

Thus, the requirement for innovative treatments and therapies is vital to enhance the outcomes of patients. One such advancement is the creation of small molecules with significantly more positive anti-cancer effects than biologics. One example of this can be found in BeyondSpring Pharmaceuticals' Plinabulin, which is predicted to transform the treatment of neutropenia.

Another factor is the growth usage of biosimilars. Biosimilars serve as an alternative to brand-name biological drugs that can significantly cut the price of treatment by 70 percent.

Novartis AG recently launched Zarxio which is a biosimilar variant of Amgen's brand-name neutropenia drug, Neupogen. These lower-cost alternatives enhance competition and exert pricing pressure, increasing the growth of the market.

For More Related Reports Click Here

Anticoccidial Drugs Market to grow from USD 1.42 Billion in 2023 to USD 1.97 Billion by 2030, at a CAGR of 3.6%.

Targeted Drug Delivery Market to grow from USD 8970 Million in 2023 to USD 25,786 Million by 2030, at a CAGR of 15.8%